MedPath

The effect of Olanzapine on the prevention of radiotherapy-induced nausea and vomiting

Phase 3
Recruiting
Conditions
Radiotherapy induced nausea and vomiting.
Nausea and vomiting
Registration Number
IRCT20170814035697N7
Lead Sponsor
Oroumia University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Complete the consent form and announce cooperation
Age over 18 years
Radiotherapy for cancer (patients undergoing chemotherapy or surgery in addition to radiotherapy)
Radiotherapy for the first time

Exclusion Criteria

Patients with proven diabetes
Patients taking anti-lipid drugs
Patients taking antipsychotic drugs, including olanzapine
Pregnant women

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The nausea and vomiting severity. Timepoint: The before, first, third and fifth days of radiotherapy. Method of measurement: questionnaire.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath